Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acut… Read more
Market Cap & Net Worth: Tetra Bio-Pharma Inc. (TBPMQ)
Tetra Bio-Pharma Inc. (PINK:TBPMQ) has a market capitalization of $84.67K ($84.67K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #41420 globally and #13473 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tetra Bio-Pharma Inc.'s stock price $0.00 by its total outstanding shares 423362824 (423.36 Million).
Tetra Bio-Pharma Inc. Market Cap History: 2015 to 2025
Tetra Bio-Pharma Inc.'s market capitalization history from 2015 to 2025. Data shows change from $15.88 Million to $84.67K (-33.57% CAGR).
Tetra Bio-Pharma Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tetra Bio-Pharma Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TBPMQ by Market Capitalization
Companies near Tetra Bio-Pharma Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Tetra Bio-Pharma Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Tetra Bio-Pharma Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Tetra Bio-Pharma Inc.'s market cap moved from $15.88 Million to $ 84.67K, with a yearly change of -33.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $84.67K | 0.00% |
| 2024 | $84.67K | -66.67% |
| 2023 | $254.02K | -96.83% |
| 2022 | $8.00 Million | -79.96% |
| 2021 | $39.92 Million | -37.47% |
| 2020 | $63.84 Million | -56.16% |
| 2019 | $145.64 Million | -44.58% |
| 2018 | $262.78 Million | -26.98% |
| 2017 | $359.86 Million | +304.95% |
| 2016 | $88.86 Million | +459.73% |
| 2015 | $15.88 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tetra Bio-Pharma Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $84.67K USD |
| MoneyControl | $84.67K USD |
| MarketWatch | $84.67K USD |
| marketcap.company | $84.67K USD |
| Reuters | $84.67K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.